Gilles Salles, MD, PhD - Differentiating Decisions in Transplant-Ineligible Relapsed/Refractory DLBCL: What Are Our Options, and How Do We Choose Between Them?

What this episode covers

Visit https://www.peervoice.com/DDU860 to view the entire programme with slides. After completing “Gilles Salles, MD, PhD - Differentiating Decisions in Transplant-Ineligible Relapsed/Refractory DLBCL: What Are Our Options, and How Do We Choose Between Them?”, participants will be able to: Assess clinical trial data evaluating approved therapies in the management of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), including chemotherapy, immunotherapy, and CAR T-cell therapy; and Formulate individualised treatment plans for patients with DLBCL upon progression to relapsed/refractory disease who are ineligible for stem-cell transplantation.

Distinct summary based on available episode metadata or transcript content.